Highlights: New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug productsSecond project proposal will ...

Purpose. The feasibility of using a limitedsampling algorithm for administration of vancomycin for treatment of vascular-access-related bacteremia in outpatient high flux hemodialysis was ...

Vancomycin 265/309 (85.8%) 76/265 (25.3%) 198/309 (64.1%) † Clinical cure is resolution of diarrhea following the recommended dose of drug (fidaxomicin: 200 mg twice a day; vancomycin ...

The trial, conducted in the United Kingdom, found that a procalcitonin-guided algorithm didn't reduce IV antibiotic duration ...

Immuron Limited (IMRN), an Australian-based biopharmaceutical company, Wednesday, announced a new research collaboration with Monash ...

based on the results of the earlier TARGET study which showed non-inferiority for the drug compared to vancomycin plus aztreonam. If it gets a green light, it will be the first antibiotic in the ...

Immuron (IMRN) announced a new research collaboration agreement with Monash University. The major objective of this research collaboration is ...

Among 547 episodes of C difficile infection documented in cancer patients in Australia and Spain, 50% were severe, and the 90 ...

Microscopic view of floating influenza virus cells. Sars. 3d rendering. Destroy The Coronavirus, Virus exploding 4k resolution Particle Technology Futuristic Design for Virus exploding , Realistic ...

Dec. 13, 2022 — Antibiotic resistance, when infection-causing bacteria evolve so they are no longer affected by typical antibiotics, is a global concern. New research has mapped the evolution ...

In an intensive Wintersession course at Brown, undergraduates learned lab techniques and performed experiments as they sought breakthrough discoveries to inform future antibiotic treatments.